Home>>Signaling Pathways>> Neuroscience>> Ophthalmology>>16-phenoxy tetranor Prostaglandin F2α methyl ester

16-phenoxy tetranor Prostaglandin F2α methyl ester (Synonyms: 16phenoxy tetranor PGF2α)

Catalog No.GC40961

Prostaglandin F2α (PGF2α) drives luteolysis and smooth muscle contraction by activating the FP receptor.

Products are for research use only. Not for human use. We do not sell to patients.

16-phenoxy tetranor Prostaglandin F2α methyl ester Chemical Structure

Cas No.: 51638-90-5

Size Price Stock Qty
500μg
$76.00
In stock
1mg
$144.00
In stock
5mg
$603.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Prostaglandin F2α (PGF2α) drives luteolysis and smooth muscle contraction by activating the FP receptor. Stable, lipophilic analogs of PGF2α are used to modulate luteolysis and treat glaucoma. 16-phenoxy tetranor Prostaglandin F2α (16-phenoxy tetranor PGF2α) is a metabolically stable form of PGF2α containing a 16-phenoxy group at the ω-terminus. It binds to the FP receptor on ovine luteal cells with much greater affinity (440%) than PGF2α. 16-phenoxy tetranor PGF2α methyl ester is a lipophilic analog of 16-phenoxy tetranor PGF2α. Methyl esters of PGs serve as prodrugs, as they are efficiently hydrolyzed in certain tissues to generate the bioactive free acid.

Reviews

Review for 16-phenoxy tetranor Prostaglandin F2α methyl ester

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 16-phenoxy tetranor Prostaglandin F2α methyl ester

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.